Psyence Biomed closed $2.0 million private placement for psilocybin-based medicines

From GlobeNewswire: 2024-12-27 16:05:35

Psyence Biomedical Ltd. closed a private placement for 1,000,000 common shares at $2.00 per share. The gross proceeds were $2.0 million, with H.C. Wainwright & Co. as the exclusive placement agent. The company plans to use the net proceeds for working capital. The securities were offered under Section 4(a)(2) of the Securities Act and have not been registered. Psyence Biomed aims to develop psilocybin-based medicines for mental health disorders. The company does not make medical claims about its products and has not conducted clinical trials. Contact information for inquiries is available on their website.



Read more at GlobeNewswire: Psyence Biomed Announces Closing of $2.0 Million Private